Multiple AbbVie team members have been serving as presenters at the 74th Annual Meeting of the American Academy of Dermatology (AAD), which began March 4 in Washington, D.C., and will wrap up on March 8.
The AbbVie researchers will unveil more than 35 abstracts on Humira (adalimumab), which has been tested in real-world and clinical venues, as a therapy for dermatologic diseases. The team will discuss Humira's effectiveness as a treatment for moderate to severe hidradenitis suppurativa (HS), as well as give an overview of HS and how it is measured in clinical settings.
Humira is also indicated for treatment of moderate to severe chronic plaque psoriasis, for which it has been tested in 16 clinical trials. The drug is also used to treat several different types of arthritis, in addition to Crohn's disease and ulcerative colitis.
"AbbVie's research presented at AAD demonstrates our ongoing commitment to making a meaningful impact on the lives of patients living with serious inflammatory skin diseases," Scott Brun, vice president of pharmaceutical development, said. "Our leadership in immunology R&D is grounded in more than 18 years of clinical trial experience, beginning with rheumatoid arthritis. We continue to explore opportunities in our clinical development programs to serve patients in need, including our research evaluating the real-world impact dermatologic diseases can have on patients."
